Patent US4198335A successfully refreshed from Google Patents.
US4198335A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antiplasmin and antiserum
Assignee: KU Leuven
•
Filing: 1977-03-08
•
Granted: 1980-04-15
•
Expires: 1997-03-08
Abstract
Abstract The invention relates to antiplasmin, a newly isolated constituent of the human blood plasma and to its method of isolation. Further, an antiplasmin-antiserum together with its preparation and utilization, and a method of determining antiplasmin in blood samples are disclosed.
Inventors
- 👤 Desire J. Collen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 03:33
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; A; A61; A61P; A61P7/00; A61P7/02; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/86; G01N2333/00; G01N2333/81; G01N2333/90; G01N2333/914; G01N2333/948; G01N2333/968; Y; Y10; Y10S; Y10S530/00; Y10S530/806; Y10S530/827; Y10S530/829; Y10S530/83
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
83 words
A method of preparing antiplasmin comprising the steps of: (a) generating an antiserum against plasmin-anti-plasmin complex, said antiserum containing a plurality of antibodies including antibodies against antiplasmin; (b) purifying the generated antiserum and recovering the said antibodies against antiplasmin; (c) insolubilizing the said antibodies against antiplasmin; (d) contacting fresh blood plasma with the said insolubilized antibodies against antiplasmin and adsorbing antiplasmin from said fresh blood plasma thereupon; and (e) recovering the said antiplasmin from the said insolubilized antibodies upon which it is adsorbed.
Claim 2
Independent Claim
83 words
A method of preparing antiplasmin comprising the steps of: (a) generating an antiserum against plasmin-anti-plasmin complex, said antiserum containing a plurality of antibodies including antibodies against antiplasmin; (b) purifying the generated antiserum and recovering the said antibodies against antiplasmin; (c) insolubilizing the said antibodies against antiplasmin; (d) contacting fresh blood plasma with the said insolubilized antibodies against antiplasmin and adsorbing antiplasmin from said fresh blood plasma thereupon; and (e) recovering the said antiplasmin from the said insolubilized antibodies upon which it is adsorbed.
Claim 3
Dependent Claim
19 words
A method as recited in claim 1, wherein the said antibodies against antiplasmin are insolubilized by coupling to 6-aminohexyl-Sepharose.
Claim 4
Dependent Claim
31 words
A method as recited in claim 1, wherein the antiserum generated against antiplasmin is purified by incubation with fresh blood plasma and purified plasminogen followed by removal of the precipitate formed.
Claim 5
Dependent Claim
31 words
A method as recited in claim 1, wherein the antiserum generated against antiplasmin is purified by incubation with antiplasmin-free blood plasma and purified plasminogen followed by removal of the precipitate formed.
Claim 6
Dependent Claim
32 words
A method as recited in claim 1, wherein the antiplasmin adsorbed upon insolubilized antibodies against antiplasmin are removed therefrom by elution with a solution of potassium cyanate or ammonium thiocyanate or glycin-HCl.
Claim 7
Dependent Claim
22 words
A method as recited in claim 1, wherein the antiplasmin separated from the insolubilized antibodies against antiplasmin is further purified by gelfiltration.
Claim 8
Dependent Claim
60 words
A method as recited in claim 1, wherein the antiplasmin obtained is used to prepared additional quantities of antiplasmin wherein the said antiplasmin is used to generate an antiserum against antiplasmin, said antiserum containing a plurality of antibodies including antibodies against antiplasmin and said generated antiserum is subjected to steps (b), (c), (d) and (e) as recited in claim 1.
Claim 9
Dependent Claim
61 words
A human antiplasmin obtained according to the method of claim 1 comprising a protein with a molecular weight of around 55,000 and an electrophoretic migration speed in agarosegel in the order of the α 2 -globulins and not showing reactions with antisera against α 2 -macroglobulin, α 1 -antitrypsin, antithrombin III, inter-α-trypsin inhibitor, C 1 -esterase inhibitor and α 1 -antichymotrypsin.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-04-15 | 1983-10-15 | 1984-04-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-04-15 | 1987-10-15 | 1988-04-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-04-15 | 1991-10-15 | 1992-04-15 | $7700.00 | Window Closed / Lapsed |